| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2001 | EP1071677A1 Production of furanones |
| 01/31/2001 | EP1071671A2 Triazolones with a neuroprotective action |
| 01/31/2001 | EP1071670A1 Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| 01/31/2001 | EP1071669A1 Bicyclic compounds having an anti-thrombitic effect |
| 01/31/2001 | EP1071668A1 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 01/31/2001 | EP1071667A1 Receptor ligands |
| 01/31/2001 | EP1071666A1 Azacycloalkane derivatives, preparation and therapeutic application |
| 01/31/2001 | EP1071665A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes |
| 01/31/2001 | EP1071664A1 Substituted 2-oxo-alkanoic acid- 2-(indol-3-yl)-ethyl] amides |
| 01/31/2001 | EP1071658A2 Btk inhibitors and methods for their identification and use |
| 01/31/2001 | EP1071655A1 Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| 01/31/2001 | EP1071646A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds |
| 01/31/2001 | EP1071645A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds |
| 01/31/2001 | EP1071474A1 Substituted porphyrins |
| 01/31/2001 | EP1071470A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 01/31/2001 | EP1071469A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071464A2 Spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin and a method of making such spray-dried tablettable powders |
| 01/31/2001 | EP1071463A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071462A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071461A1 Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition |
| 01/31/2001 | EP1071451A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071440A1 Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071432A1 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
| 01/31/2001 | EP1071431A1 Novel delivery of hydroxy carboxylic acids |
| 01/31/2001 | EP1071430A1 Treatment of iatrogenic and age-related hypertension with vitamin b6 derivatives and pharmaceutical compositions useful therein |
| 01/31/2001 | EP1071429A1 Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis |
| 01/31/2001 | EP1071428A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/31/2001 | EP1071427A1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 01/31/2001 | EP1071426A2 Novel compounds and their use as positive ampa receptor modulators |
| 01/31/2001 | EP1071425A1 Treatment of depression and pharmaceutical preparations therefor |
| 01/31/2001 | EP1071424A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| 01/31/2001 | EP1071423A1 Antagonists of gonadotropin releasing hormone |
| 01/31/2001 | EP1071422A1 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson |
| 01/31/2001 | EP1071421A1 Pharmaceutical imidazole combination for locally treating vulvovaginitis and vaginosis |
| 01/31/2001 | EP1071420A1 Indolyl-3-glyoxylic acid derivatives with antitumoral activity |
| 01/31/2001 | EP1071419A1 Cannabinoids as antioxidants and neuroprotectants |
| 01/31/2001 | EP1071418A2 New treatments for nervous disorders |
| 01/31/2001 | EP1071417A1 Use of cannabinoids as anti-inflammatory agents |
| 01/31/2001 | EP1071416A1 Inhibition of gram positive bacteria |
| 01/31/2001 | EP1071415A2 Flutamide compositions and preparations |
| 01/31/2001 | EP1071414A1 Compounds and methods for treating mitochondria-associated diseases |
| 01/31/2001 | EP1071413A1 Topical formulations for the treatment of nail fungal diseases |
| 01/31/2001 | EP1071412A2 Identification of bacterial avirulence genes and their products; vaccines and pharmaceutical compositions containing them |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071410A1 Ionic aqueous composition containing levomenthol |
| 01/31/2001 | EP1071409A2 Use of organophosphoric compounds for the therapeutic and preventative treatment of infections |
| 01/31/2001 | EP1071405A1 Method for the treatment of asthma |
| 01/31/2001 | EP1071404A2 Softgel-compatible composition containing retinol |
| 01/31/2001 | EP1071403A1 Pharmaceutical composition containing a statin and aspirin |
| 01/31/2001 | EP1071402A1 Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| 01/31/2001 | EP1071401A1 Liposomal bupivacaine compositions and methods of preparation |
| 01/31/2001 | EP1071398A1 Implants for administering substances and methods of producing implants |
| 01/31/2001 | EP1071397A2 Controlled release peroral compositions of levosimendan |
| 01/31/2001 | EP1071394A1 Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin |
| 01/31/2001 | EP1071330A1 Stabilization of isothiazolone |
| 01/31/2001 | EP1071329A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 01/31/2001 | EP1071326A1 Method of regulating appetite and metabolism |
| 01/31/2001 | EP1071325A1 Compositions and methods for antigen-specific vaccination |
| 01/31/2001 | EP0920528A4 Synthetic protein folding catalysis |
| 01/31/2001 | EP0842152B1 N-(4-substituted-benzyl)-2-aminolactam derivatives |
| 01/31/2001 | EP0837680B1 Use of phenoxy pyridine derivatives for the treatment of illnesses caused by disorders of the dopamine system |
| 01/31/2001 | EP0768884B1 Drugs containing a synergistic mixture of metronidazole and clindamycin |
| 01/31/2001 | EP0746320B1 Hiv protease inhibitors and intermediates |
| 01/31/2001 | EP0592583B1 Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282335A Phosphonocephem derivatives, process for preparation of the same, and use thereof |
| 01/31/2001 | CN1282334A Mitochondrially targeted antioxidants |
| 01/31/2001 | CN1282332A Novel acronycine compounds, preparation method and pharmaceutical compositions containing them |
| 01/31/2001 | CN1282330A Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce TNF & alpha levels |
| 01/31/2001 | CN1282329A I (ortho)-anthranilamide derivatives as anti-coagulants |
| 01/31/2001 | CN1282325A Arylthiazolidinedione derivatives |
| 01/31/2001 | CN1282322A 1,4-diazacycloheptane derivatives |
| 01/31/2001 | CN1282321A Potassium channel openers |
| 01/31/2001 | CN1282320A Thermodynamically stable from of (R)-3-[[(4-fluorophenyl) sulphonyl] amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid (ramatroban) |
| 01/31/2001 | CN1282319A Aminobutanoic acid derivatives |
| 01/31/2001 | CN1282316A Substituted cyslopentane and cyclopentene compounds useful as neuraminidase inhibitors |
| 01/31/2001 | CN1282251A Method and material for treating and preventing mucosal tissue inflammation |
| 01/31/2001 | CN1282250A Progestin therapy with controlled bleeding |
| 01/31/2001 | CN1282249A Prostaglandin E/F & alpha combination for treating impotence and enhancing sexual arousal |
| 01/31/2001 | CN1282248A Combination effective for treatment of impotence |
| 01/31/2001 | CN1282247A Stable drug composition |
| 01/31/2001 | CN1282246A Rapidly soluble drug composition |
| 01/31/2001 | CN1282245A Molecular dispersion composition with enhanced bioavailability |
| 01/31/2001 | CN1282244A Pharmaceutical compositions |
| 01/31/2001 | CN1282243A Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| 01/31/2001 | CN1282242A Multicatalytic protease inhibitors for use as anti-tumor agents |
| 01/31/2001 | CN1282241A New use of local anaesthetics against vascular headaches |
| 01/31/2001 | CN1282240A Rate controlling membranes for controlled drug delivery device |
| 01/31/2001 | CN1282239A Spheroids, preparation method and pharmaceutical compositions |
| 01/31/2001 | CN1282223A Fat blend |
| 01/31/2001 | CN1282218A Compositions and method for treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/31/2001 | CN1281862A Three-chain formed oligonucleotide capable of inhibiting platelet derived growth factor gene expression and its application |
| 01/31/2001 | CN1281852A 三唑及咪唑衍生物 Triazole and imidazole derivatives |
| 01/31/2001 | CN1281709A Chinese patent medicine for curing thrombotic disease |
| 01/31/2001 | CN1281699A Preparation of EIA-specicial medicinal compound for making medicine for resisting heat-cervical tumor and its application |
| 01/31/2001 | CN1281698A Medicine composition and its application |